Abstract
Purpose/Objective(s) Pulsed reduced dose rate (PRDR) radiation (RT) is a re-irradiation (Re-RT) technique that potentially overcomes dose/volume constraints in the setting of previous radiation therapy. While the use of this Re-RT technique has been reported for other disease sites, there is minimal data for its use for recurrent or secondary primary squamous cell carcinoma of the head and neck (HNSCC). In this study, we report preliminary data from our institution of a consecutive cohort of patients with HNSCC who received PRDR Re-RT.
Materials/Methods Out of 11 patients who received PRDR Re-RT from August 2020 to January 2023, 9 had analyzable data. Intensity modulated RT was used for treatment delivery using either volume modulated arc therapy or helical tomotherapy. A wait time between 20cGy arc/helical deliveries was used to achieve the effective low dose rate. Data collected included patient demographic information, prior interventions, diagnosis, radiation therapy dose and fractionation, progression free survival, overall survival, and toxicity rates.
Results The median time to PRDR from completion of initial RT was 13 months (range, 6-50 months). All but one patient underwent salvage surgery prior to PRDR. In total, 4 patients received systemic therapy as part of their re-treatment courses. The median follow-up after Re-RT was 7 months. The median OS from PRDR was 7 months (range, 1-32 months). Median PFS was 7 months (range, 1-32 months). One patient (11.1%) had acute grade 3 toxicity, and two patients (22.2%) had late grade 3 toxicities. There were no acute or late grade 4 or 5 toxicities.
Conclusion PRDR for Re-RT is a feasible treatment strategy for patients with recurrent or second primary HNSCC. Initial findings from this retrospective review suggest reasonable survival outcomes and potentially improved toxicity; prospective data is needed to establish the safety and efficacy of this technique.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the University of Arkansas for Medical Sciences waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
[Conflict of Interest Statement for All Authors] The authors have no conflicts of interest to disclose.
[Funding Statement] Funding: None.
[Disclosures] This data was previously presented in part at the American College of Radiation Conference in Fort Lauderdale, FL from March 9-12, 2022.
[Data Availability Statement for this Work] Research data is not available at this time.
Data Availability
Research data is not available at this time.
